Alkermes (ALKS) valuation
Alkermes P/E ratio history
Alkermes trades at 119.3 times its earnings over the last twelve months and 29.4 times the earnings analysts expect over the next twelve. At its last 3 fiscal year ends its P/E ranged from 13.2 (year to Dec 2023) to 19.6 (year to Dec 2025), with a median of 13.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $27.98 | $1.43 | 19.6 | 16.9 |
| Dec 31, 2024 | $28.76 | $2.17 | 13.3 | 14.6 |
| Dec 31, 2023 | $27.74 | $2.10 | 13.2 | 12.9 |
| Dec 31, 2022 | $26.13 | -$0.97 | n/m | — |
| Dec 31, 2021 | $23.26 | — | n/m | 36.4 |
| Dec 31, 2020 | $19.95 | -$0.70 | n/m | — |
| Dec 31, 2019 | $20.40 | -$1.26 | n/m | — |
| Dec 31, 2018 | $29.51 | -$0.89 | n/m | — |
| Dec 31, 2017 | $54.73 | -$1.03 | n/m | — |
| Dec 31, 2016 | $55.58 | -$1.37 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Alkermes valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| AlkermesALKS | $7.56B | 119.3 | 29.4 | 4.5 |
| Pacs GroupPACS | $7.57B | 28.0 | 18.2 | 1.4 |
| Axsome TherapeuticsAXSM | $7.43B | — | — | 9.6 |
| CytokineticsCYTK | $7.84B | — | — | 115.8 |
| Praxis Precision MedicinesPRAX | $7.97B | — | — | — |
| Amneal PharmaceuticalsAMRX | $6.86B | 44.8 | 19.2 | 2.2 |
| Spyre TherapeuticsSYRE | $8.38B | — | — | — |
| Arrowhead PharmaceuticalsARWR | $8.44B | — | — | 12.6 |
| HealthequityHQY | $8.57B | 37.0 | 20.0 | 6.3 |
| Peer median | 37.0 | 19.2 | 7.9 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: ALKS financials · ALKS returns
No forecast, no recommendation. This page describes Alkermes from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.